AVBP - NASDAQ
ArriVent BioPharma, Inc. Common Stock
$29.78
-0.47%ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
At a Glance
Live SnapshotArriVent BioPharma, Inc. Common Stock Management Team
Mr. Winston Kung M.B.A.
Chief Financial Officer & Treasurer
Compensation
$645,999
Ms. Yang Wang Ph.D.
Chief Technology Officer
Ms. Robin LaChapelle M.A.
Co-Founder & Chief Operating Officer
Compensation
$586,453
Dr. Zhengbin Yao Ph.D.
Co-Founder, Chairman, President & Chief Executive Officer
Compensation
$810,606
Dr. Stuart Lutzker M.D., Ph.D.
Co-Founder, President of Research & Development and Director
Compensation
$688,510
Dr. James Paul Kastenmayer J.D., Ph.D.
General Counsel & Secretary
Ms. Meghna Chowdary
Senior Vice President of Commercial Strategy
ArriVent BioPharma, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $15K and sold $12.98M worth of AVBP shares, resulting in $12.97M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
555.6K
12.98M
-13.0M
-$12.98M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
6.5K
14.83K
0
0.00
+15K
+$15K
Top Buyers
Lachapelle Robin
Officer: Chief Operating Officer
$15K
Top Sellers
Hillhouse Investment Management, Ltd.
10 Percent Owner
$12.98M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $12.97M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
AVBP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 18, 2025 | 2025 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.